Omega 3 in LES and APS

Efficacy of EPA and DHA Supplementation in Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome

It has been demonstrated that EPA and DHA supplementation may have anti-inflammatory properties in several chronic diseases, namely, diabetes, obesity, and in rheumatoid arthritis, although not with controversy. Systemic lupus erythematosus (SLE) and Antiphospholipid Antibody Syndrome (AAS) are autoimmune diseases characterized by a chronic inflammatory state which is associated with the disease´s clinical symptoms. Thus, we hypothesized that EPA and DHA supplementation may beneficially affect the inflammatory cytokine profile and clinical features of LES and AAS patients.

Inclusion Criteria:

• Age between 7 and 40 years

Exclusion Criteria:

• Cardiovascular dysfunction
• Rhythm and conduction disorders
• Musculoskeletal disturbances
• Kidney and pulmonary involvements
• Peripheral neuropathy
• Use of tobacco
• Treatment with lipid-lowering or hypoglycemic drugs
• Fibromyalgia
• Use of chronotropic or antihypertensive drugs
• Physically active subjects